PAXMAN publishes Annual Report for 2017
PAXMAN hereby publishes its Annual Report for the financial year 2017.
The Annual Report is attached to this press release, and may also be downloaded from the company’s website http://www.paxman.se/investor-centre/financial-information/?lang=en. The attached document contains a condensed version of the complete Swedish annual report “Årsredovisning 2017”. The Swedish version is also available in the printed form and can be ordered from email@example.com.
The Annual Report has been produced in cooperation with PAXMAN’s IR-partner Honeybadger, http://www.hbadger.com.
For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US)
The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser.